ALKS News 44.12 Alkermes Plc (ALKS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alkermes Plc (ALKS) 44.12 $ALKS

The Zacks Analyst Blog Highlights:GIlead, AbbVie, MannKind, Alkermes and Pharmacyclics
PR Newswire - Thu Apr 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the GIlead (Nasdaq:GILD-Free Report), AbbVie (NYSE:ABBV-Free Report), MannKind (Nasdaq:MNKD-Free Report), Alkermes (Nasdaq:ALKS-Free Report)andPharmacyclics (Nasdaq CYC-Free Report).

Research and Markets: Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
Business Wire - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t528kt/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering.

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022
M2 - Thu Apr 17, 5:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bmclnk/aripiprazole) has announced the addition of the "Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022" report to their offering. Aripiprazole lauroxil is a novel lipid ester prodrug of aripiprazole that utilizes Alkermes' proprietary LinkeRx technology for once-monthly drug delivery. Once administered IM, aripiprazole lauroxil is converted to aripiprazole, a 5-HT2A antagonist/D2 and 5-HT1A partial agonist that is marketed as Abilify by Otsuka. Alkermes' aripiprazole lauroxil differs from Otsuka/Lundbeck's once-monthly formulation of Abilify, called Abilify Depot, in that it is supplied as a suspension and does not require reconstitution prior to administration. Scope - Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aripiprazole Lauroxil including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aripiprazole Lauroxil for the top seven countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 3.1 Etiology and Pathophysiology 3.2 Symptoms 4 Disease Management 4.1 Diagnosis 4.1.1 Subjective Assessments 4.1.2 Disease Subtypes 4.2 Treatment Overview 4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 4.2.2 Maintenance Treatment of Schizophrenia 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Opportunity and Unmet Need 6.1 Unmet Needs Overview 6.1.1 Public Awareness 6.1.2 Early Diagnosis and Treatment 6.1.3 Long-Acting and Advanced Drug Delivery Systems 6.1.4 Effective Management of Negative and Cognitive Symptom Domains 6.2 Gap Analysis 6.2.1 Long-Acting Drug Delivery 6.2.2 Treatment of Negative and Cognitive Symptoms 7 Pipeline Assessment 7.1 Overview 7.2 Early-Stage Pipeline Assessment 7.3 Novel Therapeutic Approaches 7.3.1 Negative Symptoms 7.3.2 Cognitive Symptoms 7.4 Long-Acting Drug Delivery 7.5 Technology Trends Analysis 7.6 Key Drugs in Clinical Development 8 Aripiprazole Lauroxil 8.1 Overview 8.2 Efficacy 8.3 Safety 8.3.1 Dosing and Formulation 8.3.2 Potential Clinical Positioning 8.3.3 Potential Commercial Positioning 8.3.4 Pricing and Reimbursement 8.4 SWOT Analysis 8.5 Forecast 9 Appendix For more information visit http://www.researchandmarkets.com/research/bm...ipiprazole

Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.

The Biggest Biotech Wins of the Week
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 15, 5:30PM CDT
Another tough week for the biotechnology industry overshadowed impressive clinical results from several companies. Alkermes scored a big win in a difficult indication. Puma Biotechnology announced a high probability of success with its single...

Watch for Alkermes to Potentially Rebound After Falling 1.43% Yesterday
Comtex SmarTrend(R) - Mon Apr 14, 5:17PM CDT
Alkermes (NASDAQ:ALKS) traded in a range yesterday that spanned from a low of $40.57 to a high of $42.82. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $41.61 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the  SPDR S&P Biotech Index  up  22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...

Priority Reviews, Preliminary Earnings Releases, Clinical Trials Results, and Launch of Website - Analyst Notes on Gilead, Pfizer, Intuitive Surgical, Alkermes and Quest
PR Newswire - Fri Apr 11, 9:14AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), Intuitive Surgical, Inc. (NASDAQ: ISRG), Alkermes plc (NASDAQ: ALKS) and Quest Diagnostics Inc. (NYSE: DGX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/989-100free.

Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.

Halozyme Study Under Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:40PM CDT
Halozyme announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on patient enrollment and dosing of PEGPH20 in an ongoing phase II study.

ImmunoGen Up on Positive Pipeline Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 4:00PM CDT
ImmunoGen's shares have been up over a couple of trading sessions following positive pipeline results.

Gilead Announces Encouraging Sovaldi Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 3:37PM CDT
Gilead announced encouraging data on Sovaldi as a combination therapy.

Certifications, Authorizations, Stock Updates, and Upcoming Conferences - Analyst Notes on Edwards Lifesciences, Alkermes, ResMed, Auxilium, and Teleflex
PR Newswire - Thu Apr 10, 11:23AM CDT
Today, Analysts Review released its analysts' notes regarding Edwards Lifesciences Corp (NYSE: EW), Alkermes Plc (NASDAQ: ALKS), ResMed Inc. (NYSE: RMD), Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), and Teleflex Incorporated (NYSE: TFX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

3 Top-Ranked Biotech Stocks on the Rebound - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 10, 8:22AM CDT
The price correction in the biotech sector provides an opportunity to invest in stocks that are a combination of strong fundamentals and a favorable Zacks Rank.

Upgrade Alert for Alkermes (ALKS)
Comtex SmarTrend(R) - Thu Apr 10, 7:03AM CDT
Alkermes (NASDAQ:ALKS) was upgraded from Neutral to Buy at Mizuho today. The stock closed yesterday at $45.25 on volume of 1.6 million shares, above average daily volume of 1.5 million. Alkermes has overhead space with shares priced $45.25, or 5.3% below the average consensus analyst price target of $47.80. Alkermes shares should encounter resistance at the 50-day moving average (MA) of $47.65 and support at its 200-day MA of $38.84.

'Mad Money' Lightning Round: Buy, Buy, Buy Baxter
at The Street - Thu Apr 10, 5:00AM CDT
Cramer is disappointed by Boardwalk Partners, dislikes Prospect Capital but loves Kinder Morgan Energy Partners and Alkermes

Jim Cramer's 'Mad Money' Recap: Recipe for a Rally
at The Street - Wed Apr 09, 7:15PM CDT
To understand Wednesday's rally you need to know what prompted the earlier selloff, Cramer says.

Oncolytics Reports Additional Data on Reolysin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 5:30PM CDT
Oncolytics Biotech reported additional encouraging data from the REO 018 study on Reolysin.

Ambit's Oncology Drug in Phase III - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:55PM CDT
Ambit Biosciences commenced a phase III study (QUANTUM-R) on its lead oncology candidate, quizartinib for acute myeloid leukemia (AML).

Seattle Genetics Earns Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 3:20PM CDT
Seattle Genetics has earned a milestone payment of $6 million from Takeda following the first commercial sales of Adcetris in key countries.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 100

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 279

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 155

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 128

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 140

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Mar-Jac's Safety Milestone Carries Real Operational Weight

Updated Category News Views 125

Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...

Continue Reading
Linq's $90M Bet on the Infrastructure Behind AI Agents

Updated Category News Views 201

Ninety million dollars just landed on the least glamorous part of the AI-agent rush: the pipes. Linq, the San Francisco private company, announced the round on November 18, 2026, led by Andreessen Horowitz, with returning backing from TQ Ventures, Mucker Capital and Abstract, plus new money from Anthos and Left Lane Capital. Ben Horowitz is joining the board. That is a...

Continue Reading
A Parish Memoir That Sends Its Proceeds Back Home

Updated Category News Views 198

Some books arrive with a thunderclap; this one shows up carrying a folding chair, a prayer book, and a memory that refuses to leave. You Give Them Something to Eat, the new memoir from Fr. Michael J Rieder, is built from more than a hundred short chapters rather than one grand, polished life story. That choice fits the material. Parish life is rarely a clean parade of...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 84

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 10

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading

Top 5 Most Recently Viewed Articles

Mori Building Boosts Investment in SL Green’s Premier Tower

Updated Category News Views 252

Mori Building Increases Stake in Iconic One Vanderbilt Avenue In a significant development within New York’s skyline, Mori Building Co., Ltd. has expanded its investment in One Vanderbilt Avenue, acquiring an additional 5.0% interest. This comes on the heels of their earlier investment of 11.0% in 2024, marking a strong commitment to this architectural marvel situated...

Continue Reading
Vegamour Welcomes Michelle Miller as Chief Marketing Officer

Updated Category News Views 415

Vegamour Welcomes New Chief Marketing Officer Michelle Miller Vegamour is excited to announce the appointment of Michelle Miller as its first Chief Marketing Officer. A well-regarded figure in the beauty industry, Michelle brings years of experience and a proven track record of success to the company. Experience and Achievements of Michelle Miller Before joining Vegamour,...

Continue Reading
Streamlined Financing Solutions Transform Insurance Payments

Updated Category News Views 107

Revolutionizing Insurance Payments with Innovative Solutions FIRST Insurance Funding, a division of Lake Forest Bank & Trust Company, N.A., has been at the forefront of premium financing for many years. Their recent integration with ePayPolicy is set to elevate the insurance payment process, making it more accessible and user-friendly for providers and insureds alike....

Continue Reading
Range Resources Delivers Strong Q1 Results with Growth Plans

Updated Category News Views 238

Impact of Q1 2025 Results on Range Resources Range Resources Corporation (NYSE: RRC) recently revealed its first quarter financial performance, showcasing robust operating results. The company reported cash flow from operating activities reaching $330 million, highlighting strong operational efficiency. Financial Highlights for the First Quarter Key Financial Metrics In...

Continue Reading
Investing in Tomorrow: The Untapped Potential of DexCom and Roku

Updated Category News Views 122

Investing in stocks can feel like a rollercoaster ride, especially when markets take a nosedive. Historical trends remind us that, over time, stocks often bounce back. Smart investors seize opportunities during downturns to snag quality shares at bargain prices. This principle of 'buy low' remains as relevant as ever. DexCom's Dip: Opportunity or Red Flag? DexCom’s...

Continue Reading